Published in Lancet on April 07, 1990
Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes | NCT03887416
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05
The number needed to treat: a clinically useful measure of treatment effect. BMJ (1995) 13.89
The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med (2009) 12.13
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 10.66
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (2003) 8.55
Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ (1992) 5.86
Who benefits from medical interventions? BMJ (1994) 5.58
Risk factor thresholds: their existence under scrutiny. BMJ (2002) 5.55
Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ (2014) 5.55
Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ (2006) 5.03
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart (1999) 4.04
Management of raised blood pressure in New Zealand: a discussion document. BMJ (1993) 3.96
Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol (2012) 3.87
Temperature and cardiovascular mortality. BMJ (1994) 3.61
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials (2014) 3.50
By how much does dietary salt reduction lower blood pressure? III--Analysis of data from trials of salt reduction. BMJ (1991) 3.47
Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ (2004) 3.46
Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. Heart (1998) 3.31
Local confidential inquiry into avoidable factors in deaths from stroke and hypertensive disease. BMJ (1993) 3.25
Recommendations for returning genomic incidental findings? We need to talk! Genet Med (2013) 3.23
A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ (1999) 3.23
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design. J Am Med Inform Assoc (2001) 3.06
Hypertension treatment and control in sub-Saharan Africa: the epidemiological basis for policy. BMJ (1998) 2.93
The number needed to treat: a clinically useful nomogram in its proper context. BMJ (1996) 2.89
Blood pressure control in treated hypertensive patients: clinical performance of general practitioners. Br J Gen Pract (2001) 2.68
Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention. PLoS Med (2006) 2.67
What is the optimal age for starting lipid lowering treatment? A mathematical model. BMJ (2000) 2.65
Strategy for stroke. BMJ (1991) 2.43
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health (1992) 2.33
Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions. CMAJ (1997) 2.30
Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2014) 2.24
Contemporary practice patterns in the management of newly diagnosed hypertension. CMAJ (1997) 2.23
Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med (2014) 2.20
Case-control study of 24 hour ambulatory blood pressure in patients with obstructive sleep apnoea and normal matched control subjects. Thorax (2000) 2.17
Guidelines on preventing cardiovascular disease in clinical practice. BMJ (2000) 2.15
Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation (2008) 2.06
Guidelines for managing raised blood pressure. BMJ (1996) 2.03
Controversies in neurology: asymptomatic carotid stenosis--intervention or just stick to medical therapy. The argument for carotid endarterectomy. J Neural Transm (Vienna) (2011) 2.01
Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension (2008) 1.99
So stroke units save lives: where do we go from here? BMJ (1994) 1.91
Prehypertension and cardiovascular morbidity. Ann Fam Med (2005) 1.89
Arterial-ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol (1985) (2008) 1.87
Assessment and management of blood-pressure variability. Nat Rev Cardiol (2013) 1.84
Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest (2000) 1.84
Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. BMJ (1994) 1.83
Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest (1996) 1.83
Effectiveness and cost-effectiveness of blood pressure screening in adolescents in the United States. J Pediatr (2010) 1.76
Is population coronary heart disease risk screening justified? A discussion of the National Service Framework for coronary heart disease (Standard 4). Br J Gen Pract (2001) 1.74
Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension. CMAJ (1993) 1.68
Blood pressure and vascular calcification. Hypertension (2010) 1.68
Incidence and risk factors for stroke in American Indians: the Strong Heart Study. Circulation (2008) 1.67
Survival in treated hypertension: follow up study after two decades. BMJ (1998) 1.64
How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ (1993) 1.62
Cost and health consequences of reducing the population intake of salt. J Epidemiol Community Health (2000) 1.62
Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med (2011) 1.62
A blood pressure genetic risk score is a significant predictor of incident cardiovascular events in 32,669 individuals. Hypertension (2013) 1.60
Understanding clinical trials. BMJ (1994) 1.59
First line treatment in hypertension. BMJ (1990) 1.58
Diabetes mellitus and raised serum triglyceride concentration in treated hypertension--are they of prognostic importance? Observational study. BMJ (1996) 1.54
Adverse socioeconomic position across the lifecourse increases coronary heart disease risk cumulatively: findings from the British women's heart and health study. J Epidemiol Community Health (2005) 1.51
Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Hypertens Res (2014) 1.49
Teleoanalysis: combining data from different types of study. BMJ (2003) 1.48
Do changes in cardiovascular risk factors explain changes in mortality from stroke in Finland? BMJ (1995) 1.48
The virtual visit: using telecommunications technology to take care of patients. J Am Med Inform Assoc (1997) 1.46
Control of blood pressure and risk of first acute myocardial infarction: Skaraborg hypertension project. BMJ (1994) 1.46
Young Scholars Award Lecture: Intratubular angiotensinogen in hypertension and kidney diseases. Am J Hypertens (2006) 1.46
A randomized controlled trial of stress reduction in African Americans treated for hypertension for over one year. Am J Hypertens (2005) 1.45
Mobile Phone Text Messages to Support Treatment Adherence in Adults With High Blood Pressure (SMS-Text Adherence Support [StAR]): A Single-Blind, Randomized Trial. Circulation (2016) 1.45
The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future. CMAJ (2001) 1.44
Antihypertensive drugs and plasma lipids. Br Heart J (1991) 1.42
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ (2017) 1.40
Antihypertensive and adverse biochemical effects of bendrofluazide. BMJ (1990) 1.39
Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. Br J Clin Pharmacol (2008) 1.39
The Effect of Lifestyle Changes on Blood Pressure Control among Hypertensive Patients. Korean J Fam Med (2017) 1.39
Salt handling and hypertension. J Clin Invest (2004) 1.38
Rational Prescribing in Primary Care (RaPP-trial). A randomised trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice [ISRCTN48751230]. BMC Health Serv Res (2003) 1.32
Report of the Canadian Hypertension Society Consensus Conference: 2. Diagnosis of hypertension in adults. CMAJ (1993) 1.32
Cardiovascular manifestations of posttraumatic stress disorder. J Natl Med Assoc (2007) 1.31
Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970-2000. Heart (2006) 1.29
Cardiovascular and metabolic predictors of progression of prehypertension into hypertension: the Strong Heart Study. Hypertension (2009) 1.26
The use of cardiovascular risk factor information in practice databases: making the best of patient data. Br J Gen Pract (2006) 1.26
Resistant hypertension--its identification and epidemiology. Nat Rev Nephrol (2012) 1.26
Hypertension and non-insulin dependent diabetes. BMJ (1991) 1.25
Socioeconomic position in childhood and adult cardiovascular risk factors, vascular structure, and function: cardiovascular risk in young Finns study. Heart (2005) 1.25
Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. CMAJ (1999) 1.24
Observational versus experimental studies: what's the evidence for a hierarchy? NeuroRx (2004) 1.23
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J (1976) 28.28
Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol (1985) 26.13
The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst (1981) 25.60
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ (1994) 23.80
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer (1976) 22.55
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics (1973) 18.14
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
A long-term follow-up study of women using different methods of contraception--an interim report. J Biosoc Sci (1976) 13.09
The natural history of chronic airflow obstruction. Br Med J (1977) 13.04
Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet (2004) 12.59
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Body weight and mortality among women. N Engl J Med (1995) 11.04
Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol (1986) 10.84
Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ (1998) 10.71
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med (1991) 8.66
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53
Test of the National Death Index. Am J Epidemiol (1984) 8.46
Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med (1997) 8.43
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA (1989) 8.36
Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med (1997) 8.25
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17
Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet (1991) 7.87
Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health (1978) 7.80
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ (2000) 7.36
Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet (2015) 7.29
UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet (2000) 7.19
Chronic infections and coronary heart disease: is there a link? Lancet (1997) 7.18
An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ (1994) 6.74
Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet (2008) 6.67
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol (1999) 6.42
Abdominal adiposity and coronary heart disease in women. JAMA (1998) 6.21
Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ (1998) 6.13
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med (1991) 6.13
A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med (1990) 6.06
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.86
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81
Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med (2000) 5.63
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.50
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
Vitamin E consumption and the risk of coronary disease in women. N Engl J Med (1993) 5.39
The use of a self-administered questionnaire to assess diet four years in the past. Am J Epidemiol (1988) 5.32
Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA (1993) 5.31
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999) 5.27
Mortality in relation to smoking: 22 years' observations on female British doctors. Br Med J (1980) 5.21
Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med (1993) 5.19
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet (2011) 5.08
Intake of trans fatty acids and risk of coronary heart disease among women. Lancet (1993) 5.00
Postmenopausal hormone therapy and mortality. N Engl J Med (1997) 4.96
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med (1995) 4.94
The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis (1983) 4.90
Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation (1998) 4.89
Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med (2000) 4.84